It is time to change the way we manage mild asthma: an update in GINA 2019
Open Access
- 14 August 2019
- journal article
- editorial
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 1-6
Abstract
Asthma is a heterogeneous lung disease, usually characterised by chronic airway inflammation. Although evidence-based treatments are available in most countries, asthma control remains suboptimal, and asthma-related deaths continue to be an ongoing concern. Generally, it is believed that between 50 to 75% of patients with asthma can be considered as having mild asthma. Previous versions of Global Initiative for Asthma (GINA) suggested that mild asthma in adults can be well managed with either reliever medications, for example, short-acting beta2 agonists (SABA) alone or with the additional use of controllers such as regular low-dose inhaled corticosteroids (ICS). Given the low frequency or non-bothersome nature of symptoms in mild asthma, patients’ adherence towards their controller medications, especially to ICS is usually not satisfactory. Such patients often rely on SABA alone to relieve symptoms, which may contribute to SABA over-reliance. Overuse of relievers such as SABAs has been associated with poor asthma outcomes, such as exacerbations and even deaths. The new GINA 2019 asthma treatment recommendations represent significant shifts in asthma management at Steps 1 and 2 of the 5 treatment steps. The report acknowledges an emerging body of evidence suggesting the non-safety of SABAs overuse in the absence of concomitant controller medications, therefore does not support SABA-only therapy in mild asthma and has included new off-label recommendations such as symptom-driven (as-needed) low dose ICS-formoterol and “low dose ICS taken whenever SABA is taken”. The GINA 2019 report highlights significant updates in mild asthma management and these recommendations represent a clear deviation from decades of clinical practice mandating the use of symptom-driven SABA treatment alone in those with mild asthma. While the new inclusions of strategies such as symptom-driven (as-needed) ICS-formoterol and “ICS taken whenever SABA is taken” are based on several key trials, data in this context are still only emergent data, with clear superiority of as needed ICS-formoterol combinations over maintenance ICS regimens yet to be established for valid endpoints. Nevertheless, current and emerging data position the clinical asthma realm at a watershed moment with imminent changes for the way we manage mild asthma likely in going forward.Keywords
This publication has 34 references indexed in Scilit:
- Inhaled Combined Budesonide–Formoterol as Needed in Mild AsthmaNew England Journal of Medicine, 2018
- AsthmaThe Lancet, 2018
- Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012)The Lancet, 2017
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Respiratory Medicine, 2017
- Asthma Exacerbations: Pathogenesis, Prevention, and TreatmentThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) surveynpj Primary Care Respiratory Medicine, 2014
- Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendationsAllergy, 2007
- The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UKPrimary Care Respiratory Journal, 2007
- Airway Inflammation in Mild Intermittent and in Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998